A Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative Resection
A phase 3 trial of Cadonilimab in hepatocellular carcinoma, run by Akeso, now recruiting.
Overview
A Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative Resection is a phase 3 interventional study registered as NCT05489289 by Akeso, with 570 participants planned, started 2023-01-05 and due to reach its primary completion in 2026-01-28. Interventions recorded: AK104, placebo. Conditions listed: Hepatocellular Carcinoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepat
Shares Cadonilimab, Akeso, Hepatocellular carcinoma.
- TrialA Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma
Shares Cadonilimab, Akeso.
- TrialA Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC)
Shares Cadonilimab, Akeso, Hepatocellular carcinoma.
- TrialA Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC.
Shares Cadonilimab, Akeso, Hepatocellular carcinoma.
- TrialA Study of AK104/Placebo Combined With Chemoradiotherapy For The Treatment of Locally Advanced Cervical Cancer
Shares Cadonilimab, Akeso.
- TrialAn Exploratory, Multi-cohort Phase II Study of Combination Therapy With AK104 and AK112 for Recurrent Ovarian Cancer
Shares Cadonilimab, Akeso.
- TrialAK104 for Recurrent or Metastatic Vulvar Cancer
Shares Cadonilimab, Akeso.
- TrialA Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC
Shares Cadonilimab, Akeso.